Thiacetazone: Time to call a halt?: Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection
- 29 February 1996
- journal article
- editorial
- Published by Elsevier in Tubercle and Lung Disease
- Vol. 77 (1) , 27-29
- https://doi.org/10.1016/s0962-8479(96)90071-4
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- An audit of HIV testing and HIV serostatus in tuberculosis patients, Blantyre, MalawiTubercle and Lung Disease, 1995
- Accelerated course of human immunodeficiency virus infection after tuberculosis.American Journal of Respiratory and Critical Care Medicine, 1995
- Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected UgandansThe Lancet, 1994
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993
- Quantitative Bacillary Response to Treatment in HIV-associated Pulmonary TuberculosisAmerican Review of Respiratory Disease, 1993
- Cohort Study of Human Immunodeficiency Virus Infection in Patients with Tuberculosis in Nairobi, Kenya: Analysis of Early (6-Month) MortalityAmerican Review of Respiratory Disease, 1992
- Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countriesThe Lancet, 1991
- Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosisThe Lancet, 1991
- The Influence of Human Immunodeficiency Virus Infection on Tuberculosis in Kampala. UgandaAmerican Review of Respiratory Disease, 1991
- Adverse Effects of Antituberculosis DrugsDrugs, 1982